Theresa Heggie
Director/Board Member chez BIOCRYST PHARMACEUTICALS, INC.
Fortune : 324 132 $ au 31/03/2024
Profil
Theresa Marie Heggie is currently an Independent Director at BioCryst Pharmaceuticals, Inc. She is also a Co-Managing Director at Alnylam Germany GmbH and a Director at Alnylam UK Ltd.
Additionally, she serves as a Member-Supervisory Board at ProQR Therapeutics NV.
In her former positions, Ms. Heggie was the Chief Executive Officer at Shire Orphan Therapies GmbH from 2008 to 2009.
She also held the position of Chief Executive Officer at Freeline Therapeutics Ltd.
Furthermore, she served as the Chief Executive Officer & Director at Freeline Therapeutics Holdings Plc from 2020 to 2021.
Ms. Heggie was an Independent Non-Executive Director at Swedish Orphan Biovitrum AB from 2016 to 2017.
She also worked as the Vice President-Global Marketing at Baxter International, Inc. and as a Principal at Janssen Pharmaceuticals, Inc. Ms. Heggie held the position of Senior Vice President-Global Commercial Operations at Shire Plc from 2005 to 2008.
She was the Chief Marketing & Strategy Officer at The British United Provident Association Ltd.
from 2013 to 2016.
Additionally, she served as the Senior Vice President, Head-EMEA & Canada Region at Alnylam Pharmaceuticals, Inc. from 2017 to 2020.
Ms. Heggie was the Senior Vice President-Global Commercial Operations at Shire Human Genetic Therapies, Inc. from 2010 to 2013.
She also worked as a Principal at Ohmeda Pharmaceuticals.
Ms. Heggie completed her undergraduate degree at Cornell University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/02/2024 | 51 860 ( 0,03% ) | 263 449 $ | 31/03/2024 | |
PROQR THERAPEUTICS N.V.
0,03% | 31/12/2023 | 26 499 ( 0,03% ) | 60 683 $ | 31/03/2024 |
Postes actifs de Theresa Heggie
| Sociétés | Poste | Début |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Director/Board Member | 03/12/2018 |
| PROQR THERAPEUTICS N.V. | Director/Board Member | 18/05/2023 |
Alnylam Germany GmbH
 Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The private company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options. | Chief Executive Officer | - |
Alnylam UK Ltd.
 Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The private company is based in Maidenhead, UK. | Director/Board Member | 09/10/2017 |
Anciens postes connus de Theresa Heggie
| Sociétés | Poste | Fin |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Executive Officer | 15/08/2021 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2020 |
| SWEDISH ORPHAN BIOVITRUM AB | Director/Board Member | 10/04/2017 |
The British United Provident Association Ltd.
 The British United Provident Association Ltd. Life/Health InsuranceFinance The British United Provident Association Ltd. provides healthcare products and services. It offers health, dental and travel insurance, optical and audiology, and care homes. The company was founded on April 3, 1947 and is headquartered in London, the United Kingdom. | Sales & Marketing | 01/03/2016 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01/05/2013 |
Formation de Theresa Heggie
| Cornell University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| PROQR THERAPEUTICS N.V. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
The British United Provident Association Ltd.
The British United Provident Association Ltd. Life/Health InsuranceFinance The British United Provident Association Ltd. provides healthcare products and services. It offers health, dental and travel insurance, optical and audiology, and care homes. The company was founded on April 3, 1947 and is headquartered in London, the United Kingdom. | Finance |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
| Ohmeda Pharmaceuticals | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Alnylam Germany GmbH
Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The private company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options. | Health Technology |
Alnylam UK Ltd.
Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The private company is based in Maidenhead, UK. | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
